X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Eagle Genomics and Quadram Institute’s New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Content Team by Content Team
13th January 2022
in Drug Development, IPR Data Management, News
Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research, the partnership with the Quadram Institute will involve the sharing of datasets, innovation pipelines and tools to facilitate the understanding of complex microbiome data through Eagle Genomics’ e[datascientist]™ platform.

As scientists’ understanding of the role of the microbiome – the population of trillions of different bacteria and microbes that colonize our tissues, organs, and environment – and its role in both health and disease continues to improve, gaining a deeper understanding of these complex biological systems has become of vital importance. By applying advances in genetic sequencing technology, laboratories across the world can now identify which species of microbes are present in different microbiome ecosystems, and also comprehend, from reading the sequence of individual genes, which functions those microbes might have.

In addition, analysis of ‘multi-omic’ data from humans, as well as that of soil, plants, animals, and their interactions with their diverse hosts, could help scientists develop new innovations that to meet the rapidly increasing nutritional requirements of a growing global population. Such an approach would also help in reducing the carbon footprint of sectors such as food processing and agriculture.

Eagle Genomics, which is focused on driving the digitization of scientific R&D across the Food, Healthcare, Personal Care and Beauty and AgBio industries, will be working with research group leaders at the Quadram Institute to efficiently exploit multi-dimensional, multi-omic biological data. e[datascientist]™will provide the scientists with the opportunity to share their work more widely and establish new connections, in addition to using the platform to more easily interrogate, integrate and streamline new datasets. Such developments could help further advance the scientists’ research – including the potential to translate their results.

Anthony Finbow, CEO, Eagle Genomics, said: “Our new knowledge partnership with the Quadram Institute presents an exciting opportunity to share and provide access to novel datasets and tools through e[datascientist]™, providing invaluable insights in minutes rather than months.

“At Eagle Genomics, we firmly believe that the microbiome has a critical role to play across numerous industries, both now and in the future. In order better to understand these intricate relationships and unlock radical innovation opportunities, it is critical to be able to efficiently interrogate multi-dimensional microbiome data. This is where e[datascientist] is playing an invaluable role. By harnessing nature – including its complex networks and associated multi-dimensional data – we can help tackle the world’s “Grand Challenges” while unlocking significant economic potential.”

Dr. Andrew Tingey, Senior Director, Global IP and Licensing Strategy, Eagle Genomics, said: “We are delighted to be forming this new strategic partnership with the Quadram Institute and its internationally-renowned team of experts. Building a network of key knowledge partners with world-leading research institutes is a critical area of focus for us, and this latest partnership demonstrates commitment to building that network and augments our previously announced partnership with the Earlham Institute.

“We look forward to working with both Institutes and deepening our work together on our journey to becoming a global open platform for data innovation – combining open science and commercial R&D to benefit each partner and society.”

Dr. Roberto Zanchi, Head of Business Development, Quadram Institute, said: “We’re delighted to be working with Eagle Genomics on this exciting new strategic partnership. Our world-leading work on genomics and multi-omics continues to help both the UK and low- and middle-income countries around the world deliver genomic surveillance of the SARS-CoV-2 pandemic, and is built on our long-standing expertise around pathogens in the food chain.

“Data science is also absolutely key to our research at the Quadram Institute into the gut microbiome and its influence on human health, all of which is mediated by the complex interactions of micro-organisms, the food we eat, and the environment of the gastro-intestinal tract itself.”

e[datascientist]™ leverages artificial intelligence (AI) and network science in order to surface scientific connections and explore multi-causal relationships, for example to better understand the microbiome. The platform also improves the digitization, and reduces the siloization, of legacy scientific R&D systems, which can be used in tandem with datasets from publicly available databases, all in a standardized format. In this way e[datascientist] supports the entire R&D workflow, accelerating the generation of novel insights and ultimately reducing time to market.

Eagle Genomics continues to be engaged in discussions with a range of other organizations to ensure that its platform continues to become the burgeoning global life sciences knowledge discovery hub.

Previous Post

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Next Post

As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post
As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In